Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2005 May;71(5) > Minerva Anestesiologica 2005 May;71(5):207-21

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES  RESUSCITATION Freefree

Minerva Anestesiologica 2005 May;71(5):207-21

Copyright © 2005 EDIZIONI MINERVA MEDICA

language: English, Italian

Pancreas transplantation: problems and prospects in intensive care units

Bindi M. L. 1, Biancofiore G. 2, Pasquini C. 1, Lugli D. 1, Amorese G. 1, Bellissima G. 1, Fossati N. 1, Meacci L. 1, Nardi S. 1, Pieri M. 1, Vistoli F. 2, Boggi U. 2, Sansevero A. 2, Mosca F. 2

1 Postoperative Intensive Care and Transplantation Unit Department of Anesthesia and Resuscitation I Cisanello Hospital, Pisa, Italy 2 General Surgery and Transplantation Unit University of Pisa, Pisa, Italy


PDF


Aim. The aim of this study is to describe personal experience in the intensive management of patients with severe diabetes undergoing pancreas transplantation.
Methods. Clinical records of subjects consecutively undergoing an isolated or combined pancreas transplant have been examinated.
Results. During the considered period, 10 patients received an isolated pancreas transplant and 43 a simultaneous kidney-pancreas transplantation (SPKT), including 6 using a kidney from a living donor. The mean stay in the Intensive Care Unit (ICU) was 4.7 days: 52 patients (98.2%) were transferred to the Surgical Department, whereas one (1.8%) belonging to the SPKT group died with a non-functioning graft. Ten patients (18.6%) were re-admitted because of the onset of late complications, including one SPKT who died of sudden cardiac death with functioning grafts. Arterial hypertension appeared in 51% of the recipients, and 5.6% experienced at least one hypotensive episode. Cardiac rhythm alterations were diagnosed in 5 subjects (9.4%), and myocardial ischemia in 9 (17%).
Conclusion. Pancreas transplantation is a therapeutic option that can improve patients’ quality of life by also slowing down the evolution of diabetes; however, it is important to bear in mind the associated risks. The best results are obtained in patients in whom the disease has not already seriously impaired the function of the various target organs.

top of page